<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04103333</url>
  </required_header>
  <id_info>
    <org_study_id>992AN001</org_study_id>
    <nct_id>NCT04103333</nct_id>
  </id_info>
  <brief_title>Angelman Syndrome (AS) Biomarker Study</brief_title>
  <official_title>A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A)
      protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in
      support of the development of therapies for AS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ubiquitin-Protein Ligase E3A (UBE3A) Protein Levels in Each Age Group</measure>
    <time_frame>Baseline up to Day 33</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>UBE3A Protein Levels in Each Genotype Group</measure>
    <time_frame>Baseline up to Day 33</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Angelman Syndrome</condition>
  <condition>Chromosome 15q Duplication (dup15q) Syndrome</condition>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 0-6 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 7-12 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 13-18 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 19-50 years old with Angelman Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 0-6 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 7-12 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 13-18 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 19-50 years old with Dup15q Syndrome will undergo lumbar puncture (LP) for CSF and blood collection while under general anesthesia or conscious sedation during or after a prescheduled procedure unrelated to the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Puncture</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Collection</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Angelman Syndrome: Group 1</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 2</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 3</arm_group_label>
    <arm_group_label>Angelman Syndrome: Group 4</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 1</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 2</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 3</arm_group_label>
    <arm_group_label>Dup15q Syndrome: Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Ability of the participant's legally authorized representative (LAR) to understand the
             purpose and risks of the study and provide signed and dated informed consent and
             authorization to use confidential health information in accordance with national and
             local privacy regulations

          -  Must have genetically confirmed diagnosis of AS (UBE3A deletion, UBE3A mutation,
             paternal uniparental disomy, or imprinting center defect) or dup15q syndrome (with
             number and size of duplications of 15q specified) provided by the Investigator

          -  Must be scheduled for a procedure unrelated to the study that will involve
             administration of general anesthesia or conscious sedation.

        Key Exclusion Criteria:

          -  Lumbar Puncture (LP) procedure less than 30 days before the Sampling Visit

          -  Any contraindications to having an LP

          -  The blood and CSF collection will, in the opinion of the Investigator, inhibit, in
             some way, the prescheduled procedure that requires anesthesia or sedation

          -  Current enrollment or past enrollment in an interventional clinical study in which an
             investigational gene therapy or antisense oligonucleotide (ASO) is/was administered

          -  Enrollment in an interventional clinical study in which an investigational small
             molecule/antibody treatment or approved small molecule/antibody therapy for
             investigational use is administered within 1 month (or 5 half-lives of study agent,
             whichever is longer) prior to the Sampling Visit.

        Note: Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Carolina</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

